Enasidenib
Idhifa
Treatment Description
Enasidenib is an IDH2 inhibitor that is FDA approved to treat acute myeloid leukemia in patients with a specific IDH2 mutations, and being studied for use in other blood cancers.
Participating Centers
There are 146 centers running trials with this treatment. Enter a location below to find the closest center.